BBIXF (Bonus BioGroup) Debt-to-Asset : 0.44 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Bonus BioGroup Debt-to-Asset?

Bonus BioGroup's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.44 Mil. Bonus BioGroup's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $2.28 Mil. Bonus BioGroup's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $6.24 Mil. Bonus BioGroup's debt to asset for the quarter that ended in Dec. 2024 was 0.44.

Bonus BioGroup Debt-to-Asset Historical Data

The historical data trend for Bonus BioGroup's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bonus BioGroup Debt-to-Asset Chart

Bonus BioGroup Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.10

0.12

0.16

0.25

0.44

Bonus BioGroup Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.25	0.28	0.34	0.40	0.44

Competitive Comparison of Bonus BioGroup's Debt-to-Asset

For the Biotechnology subindustry, Bonus BioGroup's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bonus BioGroup's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bonus BioGroup's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Bonus BioGroup's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Bonus BioGroup Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Bonus BioGroup's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.442	+	2.276)	/	6.242
	=	0.44

Bonus BioGroup's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.442	+	2.276)	/	6.242
	=	0.44

Bonus BioGroup (OTCPK:BBIXF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Bonus BioGroup Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Bonus BioGroup's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bonus BioGroup Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bonus BioGroup Ltd (OTCPK:BBIXF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

BONS:Israel

Address

Matam Advanced, Technology Park, P.O.B 15143, Haifa, ISR, 31905

Website

https://www.bonus-bio.com

Bonus BioGroup Ltd is an clinical-stage biotechnology company developing next-generation therapies for a variety of indications in the regenerative medicine field. Its products products, BonoFill and MesenCure.

Bonus BioGroup Headlines

From GuruFocus

?Bonus BioGroup's COVID Drug - MesenCure - Can Help a Life-threatening Complication Seen in Cancer Patients

By PRNewswire PRNewswire • 04-28-2022